---
title: "Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SG)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/T14.SG.md"
symbol: "T14.SG"
name: "Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited"
industry: "Pharmaceuticals"
datetime: "2026-05-20T22:33:54.767Z"
locales:
  - [en](https://longbridge.com/en/quote/T14.SG.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/T14.SG.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/T14.SG.md)
---

# Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (T14.SG)

## Company Overview

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People’s Republic of China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | SG Market |
| Website | [www.jydrt.com.cn](https://www.jydrt.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 6 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -23.72% |  |
| Net Profit YoY | 0.68% |  |
| P/B Ratio | 2.28 |  |
| Dividend Ratio | 16.46% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3179972186.87 |  |
| Revenue | 905810967.48 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 27.71% | A |
| Profit Margin | 43.81% | A |
| Gross Margin | 77.71% | A |
| Revenue YoY | -23.72% | E |
| Net Profit YoY | 0.68% | C |
| Total Assets YoY | -1.81% | D |
| Net Assets YoY | -3.86% | D |
| Cash Flow Margin | 24.20% | D |
| OCF YoY | -23.72% | E |
| Turnover | 0.46 | C |
| Gearing Ratio | 27.92% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-23.72%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.68%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.28",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "16.46%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3179972186.87",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "905810967.48",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "27.71%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "43.81%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "77.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-23.72%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "0.68%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.81%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-3.86%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "24.20%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-23.72%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.46",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.92%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 8.16 | 1/6 | 6.46 | 5.19 | 4.65 |
| PB | 2.32 | 5/6 | 2.09 | 1.88 | 1.74 |
| PS (TTM) | 3.58 | 4/6 | 3.53 | 3.11 | 2.22 |
| Dividend Yield | 16.16% | 1/6 | 15.96% | 6.03% | 5.40% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | CMS (8A8.SG) | B | C | C | A | C | B |
| 02 | Haw Par (H02.SG) | B | D | E | A | D | C |
| 03 | TJ DaRenTang USD (T14.SG) | A | D | C | B | D | C |
| 04 | IX Biopharma (42C.SG) | D | C | C | B | C | C |
| 05 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/T14.SG/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/T14.SG/norm.md)
- [Related News](https://longbridge.com/en/quote/T14.SG/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**